

Serial No.: 09/807,657  
Group Art Unit No.: 1648

wherein ~~that~~ the immunostimulant is not a saponin derived from the bark of Quillaja Saponaria Molina.

33. An adjuvant composition as claimed in claim 32, wherein the metallic salt particle is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or berilium.

34. An adjuvant composition as claimed in claim 32, wherein the metallic salt is a phosphate or hydroxide.

35. An adjuvant composition as claimed in claim 32, wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

36. An adjuvant composition as claimed in claim 32, wherein the immunostimulant is monophosphoryl lipid A or a derivative thereof.

37. An adjuvant composition as claimed in claim 36, wherein the derivative of monophosphoryl lipid A is 3-de-O-acylated monophosphoryl lipid A.

38. (Cancelled)

39. (Twice Amended) A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a first metallic salt particle, ~~wherein the immunostimulant may be a first antigen and the first metallic salt particle is substantially free of any antigen other than the first antigen where present,~~ and b) ana second antigen ~~wherein the first antigen and the second antigen may be the same.~~

40. (Amended) A process for the manufacture of a vaccine composition as claimed in claim 39, wherein the ~~second~~ antigen is adsorbed onto a second metallic salt particle wherein the metallic salt of each of the first metallic salt particle and the second metallic salt particle may be the same.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

41. (Amended) A process as claimed in claims 39, wherein the ~~second~~ antigen is selected from the group comprising: antigens derived from Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex Virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, IgE peptides, Der p1, pollen related antigens; or Tumor associated antigens (TAA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRh (GnRH), CEA, PSA, KSA, or PRAME.

42. (Amended) A vaccine composition comprising an adjuvant composition according to any one of claims 32 to 37, additionally comprising ana ~~second~~ antigen ~~wherein the first antigen and the second antigen may be the same.~~

43. A vaccine produced according to the process claimed in any one of claims 39 to 41.

44. (Amended) A vaccine comprising a saponin adsorbed onto a metallic salt particle wherein the vaccine comprises an antigen, characterised in that the metallic salt particle is substantially free of ~~other~~ said antigen.

45. A vaccine according to claim 44, wherein the saponin is QS21.

46. A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle.

47. (Amended) A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle, characterised in that said

Serial No.: 09/807,657  
Group Art Unit No.: 1648

metallic salt particle is substantially free of immunostimulant of the first complex monophosphoryl lipid A, or a derivative thereof.

48. A vaccine composition as claimed in claims 46 or 47, wherein the metallic salt present in the first and second complexes are identical.

49. A vaccine composition as claimed in claims 46 or 47, wherein the second complex comprises a plurality of sub-complexes, each sub-complex comprising a different antigen adsorbed onto a metallic salt particle.

50. A vaccine composition as claimed in any one of claims 44 to 47, wherein the metallic salt is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or berilium.

51. A vaccine as claimed in claim 50 wherein the metallic salt is a phosphate or hydroxide.

52. A vaccine composition as claimed in claim 51 wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

53. A vaccine composition as claimed in claim 42, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

54. A vaccine composition as claimed in claim 43, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

55. A vaccine composition as claimed in claim 45, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

56. A vaccine composition as claimed in claim 46, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

57. A vaccine composition as claimed in claim 47, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

58. A vaccine composition as claimed in claim 48, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

59. A vaccine composition as claimed in claim 49, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

60. A vaccine composition as claimed in claim 50, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

61. A vaccine composition as claimed in claim 51, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

62. A vaccine composition as claimed in claim 52, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.

63. (Cancelled)

64. (Cancelled)

65. (Cancelled)

66. (Cancelled)

67. (Cancelled)

68. (Cancelled)

69. (Cancelled)

70. (Cancelled)

71. (Twice Amended) A vaccine composition as claimed in claim 42, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

72. (Twice Amended) A vaccine composition as claimed in claim 43, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

73. (Twice Amended) A vaccine composition as claimed in claim 44, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

74. (Twice Amended) A vaccine composition as claimed in claim 45, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.


75. (Twice Amended) A vaccine composition as claimed in claim 46, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus,

Serial No.: 09/807,657  
Group Art Unit No.: 1648

Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

76. (Twice Amended) A vaccine composition as claimed in claim 47, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens, or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

77. (Twice Amended) A vaccine composition as claimed in claim 48, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

 78. (Twice Amended) A vaccine composition as claimed in claim 49, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

79. (Twice Amended) A vaccine composition as claimed in claim 50, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

80. (Twice Amended) A vaccine composition as claimed in claim 51, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

81. (Twice Amended) A vaccine composition as claimed in claim 52, wherein the ~~second~~ antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, Human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, stanworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH(GnRH), CEA, PSA, tyrosinase, Survivin, KSA, or PRAME.

82. (Twice Amended) A vaccine composition as claimed in claim 71, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

83. (Twice Amended) A vaccine composition as claimed in claim 72, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

84. (Twice Amended) A vaccine composition as claimed in claim 73, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

85. (Twice Amended) A vaccine composition as claimed in claim 74, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

86. (Twice Amended) A vaccine composition as claimed in claim 75, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

87. (Twice Amended) A vaccine composition as claimed in claim 76, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

88. (Twice Amended) A vaccine composition as claimed in claim 77, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

89. (Twice Amended) A vaccine composition as claimed in claim 78, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

90. (Twice Amended) A vaccine composition as claimed in claim 79, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

91. (Twice Amended) A vaccine composition as claimed in claim 80, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.

92. (Twice Amended) A vaccine composition as claimed in claim 81, wherein the ~~second~~ antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.



Serial No.: 09/807,657  
Group Art Unit No.: 1648

93. A vaccine composition as claimed in claim 71, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

94. A vaccine composition as claimed in claim 72, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

95. A vaccine composition as claimed in claim 73, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

96. A vaccine composition as claimed in claim 74, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

97. A vaccine composition as claimed in claim 75, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

98. A vaccine composition as claimed in claim 76, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

99. A vaccine composition as claimed in claim 77, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

100. A vaccine composition as claimed in claim 78, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

101. A vaccine composition as claimed in claim 79, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

102. A vaccine composition as claimed in claim 80, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

103. A vaccine composition as claimed in claim 81, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS, S and TRAP.

104. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 71.

EV

HIV, - Page 12, line 20

Serial No.: 09/807,657  
Group Art Unit No.: 1648

105. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 72.

106. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 73.

107. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 74.

108. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 75.

109. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 76.

110. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 77.

111. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 78.

112. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 79.

113. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 80.

Serial No.: 09/807,657  
Group Art Unit No.: 1648

114. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 81.

115. A kit comprising two containers, one container having monophosphoryl lipid A, or derivative thereof, adsorbed onto a metallic salt; and the second container having antigen adsorbed onto a metallic salt.

116. (Amended) An vaccine adjuvant composition comprising: a) an immunostimulant adsorbed onto a metallic salt particle, wherein the immunostimulant ~~may be a first antigen and is~~ selected from the group consisting of bacterially derived compounds, monophosphoryl lipid A, immunostimulatory oligonucleotides, CpG, block copolymers, cholera toxin, immunostimulatory cytokines, GM-CSF, IL-1, polyriboA, polyriboU, and Muramyl tripeptide, and b) ~~ana-second~~ antigen, wherein the ~~second~~ antigen is not adsorbed onto the metallic salt particle.

117. (Withdrawn)

*E's  
concl'd*  
118. An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, wherein the metallic salt particle is substantially free of antigen and in that the immunostimulant is not a saponin derived from the bark of Quillaja Saponaria Molina.

119. A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, and b) an antigen.

---

#### REMARKS

Claims 32-37, 39-62 and 71-119 are pending in the instant application. Claims 32-37, 39-41, 43-45, 50-62, and 71-114 were rejected in the prior office action. Claims 46-49 and 115 were allowed previously. Claims 45, 46, 115, and 118 are allowed. Claims 32-45, 47, 50-62, 71-114, 116, 117 and 119 stand rejected. Claims 42, 48, and 49 are objected to. Claims 32, 39-